Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE recommends fingolimod on NHS for multiple sclerosis patients

  • Comment

NICE has given the all clear for fingolimod (Gilenya) - a pill that can help adults suffering from highly active relapsing-remitting multiple sclerosis (RRMS).

Fingolimod is the first pill-based medicine that can help reduce the number of relapses as other treatments are administered by injection.

NICE has recommended using fingolimod on adult patients who, despite taking beta interferons, are showing an unchanged or increased relapse rate or ongoing severe relapses compared to the previous year.

Around 27,500 people in England and Wales are effected by RRMS which is characterised by periods when symptoms worsen and then improve.

Professor Carole Longson, director of the Health Technology Evaluation Centre at NICE said: “Our committee concluded that fingolimod is a valuable new therapy for highly active relapsing-remitting multiple sclerosis.

“Multiple sclerosis can be a disabling condition and so we hope that this novel treatment will help to reduce relapses for these people.”


  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.